S2Medical AB (publ) (S2M.ST)
SEK 0.01
(4.55%)
SEK 0.01
(4.55%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.97 Million SEK | 49.27% |
| 2022 | 4.67 Million SEK | -39.35% |
| 2021 | 7.69 Million SEK | -69.94% |
| 2020 | 25.61 Million SEK | 726.72% |
| 2019 | 3.09 Million SEK | 107.17% |
| 2018 | 1.49 Million SEK | 77.2% |
| 2017 | 844 Thousand SEK | 148.24% |
| 2016 | 340 Thousand SEK | -77.84% |
| 2015 | 1.53 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.07 Million SEK | 72.36% |
| 2024 Q2 | 2.93 Million SEK | -28.15% |
| 2023 Q1 | 743 Thousand SEK | 13.4% |
| 2023 FY | 6.97 Million SEK | 49.27% |
| 2023 Q3 | 1.19 Million SEK | -55.36% |
| 2023 Q4 | 2.36 Million SEK | 98.49% |
| 2023 Q2 | 2.67 Million SEK | 259.35% |
| 2022 Q2 | 881 Thousand SEK | -51.46% |
| 2022 Q1 | 1.81 Million SEK | 12.89% |
| 2022 FY | 4.67 Million SEK | -39.35% |
| 2022 Q4 | 655.2 Thousand SEK | -29.92% |
| 2022 Q3 | 935 Thousand SEK | 6.13% |
| 2021 FY | 7.69 Million SEK | -69.94% |
| 2021 Q1 | 3.2 Million SEK | -35.13% |
| 2021 Q3 | 717 Thousand SEK | -67.02% |
| 2021 Q4 | 1.6 Million SEK | 124.24% |
| 2021 Q2 | 2.17 Million SEK | -32.08% |
| 2020 FY | 25.61 Million SEK | 726.72% |
| 2020 Q3 | 1.09 Million SEK | -93.41% |
| 2020 Q4 | 4.93 Million SEK | 349.42% |
| 2020 Q2 | 16.65 Million SEK | 467.91% |
| 2020 Q1 | 2.93 Million SEK | 190.45% |
| 2019 Q2 | 392 Thousand SEK | -5.08% |
| 2019 Q1 | 413 Thousand SEK | -8.75% |
| 2019 FY | 3.09 Million SEK | 107.17% |
| 2019 Q4 | 1 Million SEK | -21.38% |
| 2019 Q3 | 1.28 Million SEK | 227.55% |
| 2018 Q2 | 456 Thousand SEK | 150.55% |
| 2018 FY | 1.49 Million SEK | 77.2% |
| 2018 Q4 | 452.58 Thousand SEK | 11.75% |
| 2018 Q3 | 405 Thousand SEK | -11.18% |
| 2018 Q1 | 182 Thousand SEK | -78.96% |
| 2017 Q2 | 124 Thousand SEK | 0.0% |
| 2017 Q3 | 865.13 Thousand SEK | 597.69% |
| 2017 FY | 844 Thousand SEK | 148.24% |
| 2017 Q1 | 124 Thousand SEK | 0.0% |
| 2017 Q4 | 865.13 Thousand SEK | 0.0% |
| 2016 FY | 340 Thousand SEK | -77.84% |
| 2015 FY | 1.53 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AddLife AB (publ) | 9.68 Billion SEK | 99.928% |
| Biotage AB (publ) | 1.86 Billion SEK | 99.626% |
| Bonesupport Holding AB (publ) | 591.07 Million SEK | 98.821% |
| Doxa AB (publ) | 9.9 Million SEK | 29.582% |
| Elekta AB (publ) | 18.11 Billion SEK | 99.962% |
| iZafe Group AB (publ) | 1.82 Million SEK | -282.621% |
| Ortivus AB (publ) | 84.08 Million SEK | 91.709% |
| Ortivus AB (publ) | 84.08 Million SEK | 91.709% |
| Q-linea AB (publ) | 4.44 Million SEK | -57.012% |
| Synsam AB (publ) | 5.9 Billion SEK | 99.882% |